Siegfried Holding AG (SGFEF) Stock Analysis

Siegfried Holding AG (SGFEF) Healthcare & Pipeline Overview

Siegfried Holding AG, a Swiss-based life sciences company with a market cap of $3.12B, specializes in developing and manufacturing APIs and finished dosage forms. With a presence in key global markets, Siegfried offers contract development and manufacturing services, leveraging a 150+ year history and a 12.7% profit margin to serve the pharmaceutical industry.

What Is the Investment Thesis for SGFEF?

The company's consistent profitability, with a 12.7% profit margin, and a stable dividend yield of 0.49% indicate financial health. Growth catalysts include expanding CDMO contracts and increasing demand for sterile injectables and specialized APIs. Key value drivers are the company's ability to maintain high-quality standards, its strategic partnerships, and its investments in new technologies. Potential risks include regulatory changes in the pharmaceutical industry and competition from larger CDMOs. The company's beta of 0.74 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

SGFEF Key Highlights

Market capitalization of $3.12B indicates a significant presence in the specialty and generic drug manufacturing industry.

• P/E ratio of 18.14 suggests a reasonable valuation compared to earnings, reflecting investor confidence in future growth.
• Profit margin of 12.7% demonstrates efficient operations and strong pricing power within its market segments.
• Gross margin of 26.7% indicates the company's ability to manage production costs effectively.
• Dividend yield of 0.49% provides a modest income stream for investors, reflecting a commitment to shareholder returns.

Who Are SGFEF's Competitors?

SGFEF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are SGFEF's Key Strengths?

Strong expertise in API and finished dosage form development and manufacturing.

• Established relationships with pharmaceutical clients.
• Diverse product portfolio.
• Global manufacturing network.

What Are SGFEF's Weaknesses?

Reliance on a limited number of key clients.

• Exposure to regulatory changes and compliance risks.
• Competition from larger CDMOs.
• OTC market trading may limit liquidity.

What Could Drive SGFEF Stock Higher?

Expansion of CDMO contracts with pharmaceutical companies.

• Increasing demand for sterile injectables and specialized APIs.
• Strategic partnerships and acquisitions to expand capabilities.
• Investment in new technologies and manufacturing facilities.
• Geographic expansion into emerging markets.

What Are the Key Risks for SGFEF?

Regulatory changes in the pharmaceutical industry.

• Increased competition from larger CDMOs.
• Pricing pressures from generic drug manufacturers.
• Patent expirations and loss of exclusivity.
• Limited liquidity due to OTC market trading.

What Are the Growth Opportunities for SGFEF?

• Expansion of CDMO Services: Siegfried can capitalize on the growing demand for outsourced pharmaceutical development and manufacturing services. The global CDMO market is projected to reach $225.2 billion by 2028, growing at a CAGR of 6.9% from 2021. By expanding its capacity and capabilities in areas such as sterile injectables and complex APIs, Siegfried can attract new clients and increase its market share. Timeline: Ongoing.
• Strategic Partnerships and Acquisitions: Siegfried can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Collaborating with other pharmaceutical companies or acquiring specialized CDMOs can provide access to new markets and expertise. The pharmaceutical industry is increasingly reliant on partnerships to drive innovation and growth. Timeline: Ongoing.
• Focus on Specialized APIs: Siegfried can focus on developing and manufacturing specialized APIs, particularly those used in anesthetics, pain treatment, and central nervous system disorders. These APIs often have higher margins and less competition compared to generic APIs. The global market for APIs is expected to reach $273.4 billion by 2027, growing at a CAGR of 6.1% from 2020. Timeline: Ongoing.
• Investment in Sterile Injectables: Siegfried can invest in expanding its sterile injectable manufacturing capabilities to meet the growing demand for these products. The global market for sterile injectables is projected to reach $738.9 billion by 2027, growing at a CAGR of 9.8% from 2020. This growth is driven by the increasing prevalence of chronic diseases and the development of new biologic drugs that require sterile administration. Timeline: Ongoing.
• Geographic Expansion: Siegfried can expand its geographic presence by establishing new manufacturing facilities or acquiring existing facilities in key markets such as Asia and North America. This would allow the company to better serve its global clients and reduce its reliance on its existing manufacturing sites. The pharmaceutical market in Asia is growing rapidly, driven by increasing healthcare spending and a growing aging population. Timeline: Ongoing.

What Are SGFEF's Competitive Advantages?

• Specialized Expertise: Siegfried possesses specialized expertise in the development and manufacturing of complex APIs and finished dosage forms, which creates a barrier to entry for new competitors.
• Long-Standing Relationships: The company has established long-standing relationships with its clients, providing a stable source of revenue and repeat business.
• Regulatory Compliance: Siegfried maintains high standards of regulatory compliance, which is essential for operating in the pharmaceutical industry.
• Manufacturing Capabilities: The company has invested in advanced manufacturing facilities and technologies, which allows it to produce high-quality products efficiently.

What Does SGFEF Do?

Siegfried Holding AG, founded in 1873 and headquartered in Zofingen, Switzerland, operates within the life sciences sector, focusing on the development and production of active pharmaceutical ingredients (APIs) and finished dosage forms. The company's comprehensive service portfolio includes contract development and manufacturing (CDMO) services, catering to pharmaceutical companies globally. Siegfried's offerings span pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale-up and clinical trial material production. Siegfried manufactures a diverse range of finished dosage forms, including solid oral dosage forms, sterile and aseptic filling injectables, ophthalmics, and inhalative products. The company also produces APIs and controlled substances, with a focus on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Additionally, Siegfried licenses oral solid and sterile products, assembles registration dossiers, and offers common technical documents for various products. Siegfried's long history in the pharmaceutical industry has allowed it to establish a strong reputation for quality and reliability. The company serves a global clientele, providing essential services and products to support the development and manufacturing of pharmaceuticals. With a workforce of 3,886 employees, Siegfried continues to expand its capabilities and geographic reach to meet the evolving needs of the pharmaceutical market.

What Products and Services Does SGFEF Offer?

• Develops and produces active pharmaceutical ingredients (APIs).
• Manufactures pharmaceutical intermediates.
• Produces finished dosage forms, including solid oral dosages.
• Offers sterile and aseptic filling for injectables.
• Manufactures ophthalmics and inhalative products.
• Provides contract development and manufacturing services (CDMO).
• Licenses oral solid and sterile products.
• Assembles registration dossiers for pharmaceutical products.

How Does SGFEF Make Money?

• Contract development and manufacturing (CDMO) services for pharmaceutical companies.
• Development and manufacturing of active pharmaceutical ingredients (APIs).
• Production of finished dosage forms, including oral solids and sterile injectables.
• Licensing of pharmaceutical products and technologies.

What Industry Does SGFEF Operate In?

Siegfried Holding AG operates in the specialty and generic drug manufacturing industry, a sector characterized by increasing demand for outsourced pharmaceutical development and manufacturing services. The global CDMO market is expected to continue growing, driven by factors such as the rising cost of drug development, the increasing complexity of pharmaceutical products, and the growing focus on personalized medicine. Siegfried competes with other CDMOs, including CZMWF (Croma-Pharma GmbH), CZMWY (Croma-Pharma GmbH), DNPUF (DNP Corporation), HKMPF (Hoya Corporation), and HKMPY (Hoya Corporation), as well as larger pharmaceutical companies with in-house manufacturing capabilities.

Who Are SGFEF's Key Customers?

• Pharmaceutical companies seeking outsourced development and manufacturing services.
• Generic drug manufacturers requiring APIs and intermediates.
• Biopharmaceutical companies needing sterile filling and finishing services.
• Companies licensing pharmaceutical products and technologies.

Siegfried Holding AG Financial Trajectory

Siegfried Holding AG (SGFEF) reported $771.5M in revenue for Q2 FY2026, a decline of 11.2% compared to the prior quarter. The company recorded net income of $83.0M, with diluted EPS of $1.89. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, SGFEF averaged $7.92 in diluted EPS.

Company Profile

Siegfried Holding AG operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Zofingen, CH. The company is led by CEO Marcel Imwinkelried. SGFEF has traded publicly since 2014.

How Siegfried Holding AG Is Valued

Siegfried Holding AG carries a market capitalization of $3.12B, placing it in the mid-cap category.

Return on equity for Siegfried Holding AG stands at 16.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.1%, showing how much profit it generates from its asset base. SGFEF trades at a trailing price-to-earnings ratio of 18.14, below the Healthcare sector average of ~21.50x. Its free cash flow yield is -0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.45 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.5%, the inverse of the P/E and a quick read on earnings relative to price.

Siegfried Holding AG's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.79 places it in the safe zone, indicating low near-term bankruptcy risk.

Siegfried Holding AG has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.0% above estimates on average.

SGFEF Financials

SGFEF Latest News

SGFEF Analyst Consensus

SGFEF MoonshotScore

What Investors Ask About Siegfried Holding AG (SGFEF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources